Author | Gregory Vidal, MD, PhD | OncLive

Author | Gregory Vidal, MD, PhD

Articles

Dr. Vidal on the Use of CDK4/6 Inhibitors in HER2+ Breast Cancer

January 04, 2020

Video

Gregory Vidal, MD, PhD, assistant professor, Department of Hematology/Oncology, The University of Tennessee Health Science Center, and medical oncologist, West Cancer Center, discusses the potential use of CDK4/6 inhibitors in HER2-positive breast cancer.

Dr. Vidal on Choosing Between Available Trastuzumab Biosimilars

December 04, 2019

Video

Gregory Vidal, MD, PhD, discusses how the field will determine which trastuzumab (Herceptin) biosimilar to prescribe in clinical practice.

Dr. Vidal on Potential of [Fam-] Trastuzumab Deruxtecan in HER2+ Breast Cancer

November 15, 2019

Video

Gregory Vidal, MD, PhD, discusses the potential of [fam-] trastuzumab deruxtecan in HER2-positive breast cancer.

Dr. Vidal on Increasing Access to HER2-Targeted Therapy With Biosimilars

November 04, 2019

Video

Gregory Vidal, MD, PhD, explains how biosimilars could increase access to HER2-targeted therapy.

x